• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP.

作者信息

Bewarder Moritz, Kaddu-Mulindwa Dominic, Kos Igor Age, Lesan Vadim, Held Gerhard, Poeschel Viola, Thurner Lorenz, Bittenbring Joerg Thomas, Schmitz Norbert, Truemper Lorenz, Pfreundschuh Michael, Christofyllakis Konstantinos, Loeffler Markus, Altmann Bettina, Ziepert Marita

机构信息

Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical Center, Homburg/Saar.

Department of Internal Medicine 1, Westpfalz-Klinikum, Kaiserslautern.

出版信息

Haematologica. 2023 Oct 1;108(10):2844-2849. doi: 10.3324/haematol.2022.282126.

DOI:10.3324/haematol.2022.282126
PMID:36815369
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10543194/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0251/10543194/7117708e2d69/1082844.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0251/10543194/33da6572078e/1082844.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0251/10543194/7117708e2d69/1082844.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0251/10543194/33da6572078e/1082844.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0251/10543194/7117708e2d69/1082844.fig2.jpg

相似文献

1
Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP.长春新碱剂量降低对接受（R）-CHOP方案治疗的侵袭性B细胞淋巴瘤患者预后的影响。
Haematologica. 2023 Oct 1;108(10):2844-2849. doi: 10.3324/haematol.2022.282126.
2
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.老年弥漫性大B细胞淋巴瘤患者中，CHOP化疗联合利妥昔单抗与单纯CHOP化疗的比较。
N Engl J Med. 2002 Jan 24;346(4):235-42. doi: 10.1056/NEJMoa011795.
3
Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.剂量调整的EPOCH-利妥昔单抗或强化B-NHL疗法用于儿童原发性纵隔大B细胞淋巴瘤。
Haematologica. 2021 Dec 1;106(12):3232-3235. doi: 10.3324/haematol.2021.278971.
4
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.剂量调整的EPOCH-R方案（依托泊苷、泼尼松、长春新碱、环磷酰胺、阿霉素和利妥昔单抗）用于治疗未经治疗的伴有MYC重排的侵袭性弥漫性大B细胞淋巴瘤：一项前瞻性、多中心、单臂2期研究。
Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.
5
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.在预后良好的侵袭性 B 细胞淋巴瘤患者中，与六次利妥昔单抗联合使用相比，四个与六个周期的 CHOP 化疗（FLYER）：一项随机、3 期、非劣效性试验。
Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9.
6
CHOP plus rituximab--balancing facts and opinion.环磷酰胺、阿霉素、长春新碱、强的松联合利妥昔单抗——权衡事实与观点。
N Engl J Med. 2002 Jan 24;346(4):280-2. doi: 10.1056/NEJM200201243460411.
7
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.伊布替尼联合利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）治疗初治 CD20 阳性 B 细胞非霍奇金淋巴瘤患者：一项非随机、1b 期研究。
Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.
8
Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.利妥昔单抗联合环磷酰胺/阿霉素/长春新碱/泼尼松（CHOP）治疗干燥综合征相关B细胞侵袭性非霍奇金淋巴瘤。
Rheumatology (Oxford). 2004 Aug;43(8):1050-3. doi: 10.1093/rheumatology/keh248. Epub 2004 Jun 8.
9
Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?剂量调整后的EPOCH-R方案在儿童原发性纵隔B细胞淋巴瘤患者中比在成人患者中疗效更差吗？
J Clin Oncol. 2022 Jun 20;40(18):2063-2064. doi: 10.1200/JCO.21.02593. Epub 2022 Apr 4.
10
Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.免疫化疗是老年弥漫性大B细胞淋巴瘤患者的标准治疗方法。
Blood. 2004 Sep 1;104(5):1584-5; author reply 1585-6. doi: 10.1182/blood-2004-04-1266.

引用本文的文献

1
Prognostic impact of RDI of vincristine in patients with DLBCL receiving R-CHOP: a supplementary analysis of JCOG0601.接受R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者中长春新碱相对剂量强度的预后影响：JCOG0601的补充分析
Blood Neoplasia. 2025 Feb 16;2(2):100077. doi: 10.1016/j.bneo.2025.100077. eCollection 2025 May.
2
An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma.CEP72 基因的遗传性遗传变异与侵袭性 B 细胞淋巴瘤女性患者长春新碱诱导的周围神经病的发展有关。
Ann Hematol. 2024 Nov;103(11):4599-4606. doi: 10.1007/s00277-024-05973-9. Epub 2024 Sep 4.

本文引用的文献

1
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.泊洛妥珠单抗联合化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤
N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14.
2
Diffuse Large B-Cell Lymphoma.弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2021 Mar 4;384(9):842-858. doi: 10.1056/NEJMra2027612.
3
Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCL.在弥漫性大B细胞淋巴瘤治疗中，从R-CHOP方案中省略/减少长春新碱的影响。
Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):162-169. doi: 10.1016/j.clml.2020.12.017. Epub 2020 Dec 23.
4
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update.成人癌症幸存者化疗诱导性周围神经病的预防和管理：ASCO 指南更新。
J Clin Oncol. 2020 Oct 1;38(28):3325-3348. doi: 10.1200/JCO.20.01399. Epub 2020 Jul 14.
5
Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?弥漫性大 B 细胞淋巴瘤患者中省略长春新碱是否会影响治疗结果？
Ann Hematol. 2018 Nov;97(11):2129-2135. doi: 10.1007/s00277-018-3437-z. Epub 2018 Aug 8.
6
Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma.利妥昔单抗联合环磷酰胺、阿霉素、长春新碱及泼尼松方案（R-CHOP）中长春新碱剂量减少对弥漫性大B细胞淋巴瘤预后的影响
Ann Hematol. 2016 Jan;95(1):41-47. doi: 10.1007/s00277-015-2514-9. Epub 2015 Oct 5.
7
Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.欧洲形态亚型血液系统恶性肿瘤的发病率：HAEMACARE 项目的结果。
Blood. 2010 Nov 11;116(19):3724-34. doi: 10.1182/blood-2010-05-282632. Epub 2010 Jul 27.
8
Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management.与微管抑制剂相关的神经病变：诊断、发病率及管理
Clin Adv Hematol Oncol. 2008 Jun;6(6):455-67.
9
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.在预后良好的年轻弥漫性大B细胞淋巴瘤患者中，CHOP样化疗联合利妥昔单抗对比单纯CHOP样化疗：美罗华国际试验（MInT）组的一项随机对照试验
Lancet Oncol. 2006 May;7(5):379-91. doi: 10.1016/S1470-2045(06)70664-7.
10
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.1992 - 2001年美国按世界卫生组织亚型划分的淋巴瘤发病模式。
Blood. 2006 Jan 1;107(1):265-76. doi: 10.1182/blood-2005-06-2508. Epub 2005 Sep 8.